SCHEMBL16147241

SCHEMBL16147241

COC(=O)c1cc(CNC(=O)OC(C)(C)C)cc(C(=O)OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.44
KDM4A O75164 1/20 0.44
NAMPT P43490 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
SERPINE1 P05121 1/20 0.43
HDAC1 Q13547 1/20 0.43
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
GLS O94925 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16405266 0.91 SLC7A5 (0.49) HIF1AKDM4ANAMPTL3MBTL1SERPINE1
SCHEMBL21711869 0.90 NOTUM (0.47) HIF1AKDM4ANAMPTL3MBTL1SERPINE1
SCHEMBL8129924 0.90 HDAC1 (0.40) HIF1AKDM4ANAMPTL3MBTL1SERPINE1
SCHEMBL3877931 0.90 GRM2 (0.41) HIF1AKDM4ANAMPTL3MBTL1SERPINE1
SCHEMBL21712030 0.88 NOTUM (0.51) KDM4ANAMPTL3MBTL1SERPINE1HDAC1
SCHEMBL16147999 0.86 HDAC1 (0.46) KDM4ANAMPTL3MBTL1HDAC1MEN1
SCHEMBL879574 0.85 LOXL2 (0.56) HIF1AKDM4ANAMPTGLSLOXL2
SCHEMBL13055397 0.85 KDM4A (0.51) KDM4ANAMPTL3MBTL1HDAC1LMNA
SCHEMBL1206337 0.84 NAMPT (0.55) NAMPTL3MBTL1HDAC1ALDH1A1LMNA
SCHEMBL18019821 0.84 DYRK1A (0.50) KDM4ANAMPTL3MBTL1HDAC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10344060-B2 Potent and selective inhibitors of Nav1.7 AMGEN INC. (US) 2019-07-09 US disclosed
US-10344060-B2 Potent and selective inhibitors of Nav1.7 AMGEN INC. (US) 2019-07-09 US disclosed
EP-2970408-B1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 AMGEN INC (US) 2018-01-10 EP disclosed
US-9636418-B2 Potent and selective inhibitors of NAV1.7 AMGEN INC. (US) 2017-05-02 US disclosed
US-9636418-B2 Potent and selective inhibitors of NAV1.7 AMGEN INC. (US) 2017-05-02 US disclosed
US-20160024159-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 AMGEN INC. (US) 2016-01-28 US disclosed
US-20160024159-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 AMGEN INC. (US) 2016-01-28 US disclosed
EP-2970408-A2 POTENT AND SELECTIVE INHIBITORS OF Nav1.7 Amgen Inc. (US) 2016-01-20 EP disclosed
US-20150023988-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 AMGEN INC. (US) 2015-01-22 US disclosed
US-20150023988-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 AMGEN INC. (US) 2015-01-22 US disclosed
WO-2014165277-A2 POTENT AND SELECTIVE INHIBITORS OF Nav1.7 AMGEN INC. (US) 2014-10-09 WO disclosed
WO-2014165277-A2 POTENT AND SELECTIVE INHIBITORS OF Nav1.7 AMGEN INC. (US) 2014-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344060-B2 Potent and selective inhibitors of Nav1.7 SCN7A, SCN9A, SCN1A HIF1A 3622/4885KDM4A 2034/4885NAMPT 1056/4885
US-20150023988-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 SCN7A, SCN9A, SCN1A HIF1A 3622/4885KDM4A 2034/4885NAMPT 1056/4885
US-20160024159-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 SCN7A, SCN9A, SCN1A HIF1A 3622/4885KDM4A 2034/4885NAMPT 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.